InvestorsObserver is giving Catalyst Pharmaceuticals Inc (CPRX) an Analyst Rating Rank of 79, meaning CPRX is ranked higher by analysts than 79% of stocks. The average projection by analysts for CPRX is $7.4 over the next 12 months and analyst’s classify the stock as a Strong Buy
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Catalyst Pharmaceuticals Inc Stock Today?
Catalyst Pharmaceuticals Inc (CPRX) stock is trading at $3.60 as of 12:16 PM on Thursday, Dec 3, a rise of $0.06, or 1.7% from the previous closing price of $3.54. The stock has traded between $3.55 and $3.65 so far today. Volume today is light. So far 704,036 shares have traded compared to average volume of 1,384,920 shares.
Click Here to get the full report on Catalyst Pharmaceuticals Inc (CPRX) Stock.
